• Aptar Pharma’s LuerVax intranasal vaccine delivery device gets CE mark

  Aptar Pharma’s LuerVax single-use nasal vaccine delivery device is now CE marked, the company announced. An optional accessory that allows for division of the vaccine so that half of the dose can be sprayed into… [Read more . . .]

• Liquidia settles with United Therapeutics, Yutrepia treprostinil DPI will continue to be available for PAH

  According to Liquidia, the company has reached a settlement with United Therapeutics to end all litigation related to patent infringement by Liquidia’s Yutrepia treprostinil DPI. A United States District Court judge recently ruled that Yutrepia… [Read more . . .]

• Aptar announces the addition of OINDP manufacturing capacity at its Mumbai, India facility

  Aptar Pharma has announced the addition of molding capabilities to its OINDP manufacturing facility in Mumbai, India, which was opened in 2023. Products produced at the plant include MDI valves, breath-actuated inhalers, and nasal delivery devices.… [Read more . . .]

• Bespak to offer nasal dry powder delivery device under MOU with SNBL

  CDMO Bespak, which recently said that it had partnered with Upperton to offer nasal drug/device development and manufacturing and launched a new soft mist intranasal delivery device, has announced that it will now offer access… [Read more . . .]

• Lupin launches Formoflo-G glypocyrronium / formoterol / fluticasone MDI for the treatment of COPD in India

  Lupin has announced the approval of its Formoflo-G glypocyrronium / formoterol / fluticasone propionate MDI for the treatment of COPD by the Drug Controller General of India (DCGI) and the subsequent launch of the inhaler… [Read more . . .]

• Liquidia to submit sNDA to remove PH-ILD indication from Yutrepia treprostinil DPI after court finds that it infringes claims in United Therapeutics patent covering Tyvaso

• Bespak launches its new NasaDose Ultra Soft Unit Dose Spray nasal delivery device

• Nasus Pharma initiates Phase 1 trial of NS003 intranasal dry powder ondansetron

• Mosanna Therapeutics says data from Phase 1 trial of MOS118 nasal spray in healthy volunteers supports advancement into patients with sleep apnea

• Tiziana initiates Phase 2a BANYAN trial of intranasal foralumab in patients with ALS

More news . . .